Inclusion Criteria:

          1. Written informed consent prior to beginning specific protocol procedures, including
             expected cooperation of the patients for the treatment and follow-up, must be obtained
             and documented according to the local regulatory requirements.

          2. Age at diagnosis at least 18 years.

          3. Willingness and ability to provide archived formalin fixed paraffin embedded tissue
             (FFPE) block from surgery after neoadjuvant chemotherapy and from core biopsy before
             start of neoadjuvant chemotherapy, which will be used for centralized prospective
             confirmation of HR status, HER2 status, Ki-67 and tumor-infiltrating lymphocytes
             (TILs) and for retrospective exploratory correlation between genes, proteins, and
             mRNAs relevant to sensitivity/resistance to the investigational agents. For patients
             with bilateral carcinoma, FFPE blocks from both sides have to be provided for central
             testing.

          4. Histologically confirmed unilateral or bilateral primary invasive carcinoma of the
             breast, confirmed histologically by core biopsy. The lead tumor has to be defined by
             the investigator based on the inclusion criteria for the respective subtype and on the
             risk status.

          5. Centrally confirmed HER2-negative (IHC score 0-1 or FISH negative according to
             ASCO/CAP guideline) and either

               -  HR-positive (≥1% positive stained cells) disease or

               -  HR-negative (<1% positive stained cells) assessed preferably on tissue from
                  postneoadjuvant residual invasive disease of the breast, or if not possible, of
                  residual nodal invasion. If not evaluable, core of diagnostic biopsy will be
                  used. In case of bilateral breast cancer, HER2-negative status has to be
                  confirmed for both sides.

          6. Patients with residual invasive disease after neoadjuvant chemotherapy at high risk of
             recurrence defined by either:

               -  For HR-negative: any residual invasive disease > ypT1mi

               -  For HR-positive disease: a CPS+EG score ≥ 3 or CPS+EG score 2 and ypN+ using
                  local ER and grade assessed on core biopsies taken before start of neoadjuvant
                  treatment.

          7. Germline BRCA1/2 mutated or wildtype/unknown.

          8. Adequate surgical treatment including resection of clinically evident disease and
             ipsilateral axillary lymph node dissection. SNB before NACT is discouraged. Axillary
             dissection before NACT is not permitted. Axillary dissection is not required in
             patients with a negative sentinel-node biopsy before (pN0, pN+(mic)) or after (ypN0,
             ypN+(mic)) neoadjuvant chemotherapy. Histologic complete resection (R0) of all
             invasive and in situ tumors is required.

          9. Patients must have received neoadjuvant taxane-based chemotherapy for 16 weeks
             (anthracyclines are permitted). This period must include 6 weeks of a taxane
             containing neoadjuvant chemotherapy (exception: for patients with progressive disease
             that occurred after at least 6 weeks of taxane-containing neoadjuvant chemotherapy, a
             total treatment period of less than 16 weeks is also eligible).

         10. No clinical evidence for locoregional or distant relapse during or after preoperative
             chemotherapy. Local progression during chemotherapy is not an exclusion criterion if
             adequate local control could be obtained.

         11. In case of local progression during neoadjuvant therapy, distant metastases must be
             excluded by adequate imaging (CT/MRI recommend) prior to entering the trial.

         12. Immune checkpoint inhibitor / immunotherapy during neoadjuvant therapy is allowed.

         13. An interval of less than 16 weeks since the date of final surgery or less than 10
             weeks from completing radiotherapy (whichever occurs last) and the date of
             randomization is required.

         14. Radiotherapy should be delivered before the start of study treatment. Radiotherapy to
             the breast is indicated in all patients with breast conserving surgery and to the
             chest wall and lymph nodes according to local guidelines as well as in all patients
             with cT3/4 or ypN+ disease treated by mastectomy.

         15. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

         16. Resolution of all acute toxic effects of prior anti-cancer therapy or surgical
             procedure or radiotherapy to NCI CTCAE v 5.0 grade ≤ 1 (except alopecia or other
             toxicities not considered a safety risk for the patients at the investigator´s
             discretion).

         17. Estimated life expectancy of at least 5 years irrespective of the diagnosis of breast
             cancer.

         18. The patient must be accessible for scheduled visits, treatment and follow-up.

         19. Normal cardiac function after neoadjuvant chemotherapy must be confirmed according to
             local guidelines. Results for LVEF must be above the normal limit of the institution.

         20. Laboratory requirements:

             Hematology

               -  Absolute neutrophil count (ANC) ≥1.5 x 109 / L

               -  Platelets ≥100 x 109 / L

               -  Hemoglobin ≥10 g/dL (≥6.2 mmol/L) Hepatic function

               -  Total bilirubin <1.25x UNL

               -  AST and ALT ≤1.5x UNL

               -  Alkaline phosphatase ≤2.5x UNL Renal Function

               -  <1.25x ULN creatinine or creatinine clearance ≥30 ml/min (according to
                  Cockroft-Gault, if creatinine is above UNL).

         21. Negative pregnancy test (urine or serum) within 14 days prior to randomization for all
             women of childbearing potential. A woman is considered to be of childbearing potential
             if she is not postmenopausal. Postmenopausal is defined as:

               -  Age ≥60 years

               -  Age <60 years and ≥12 continuous months of amenorrhea with no identified cause
                  other than menopause

               -  Surgical sterilization (bilateral oophorectomy and/or hysterectomy).

         22. For women of childbearing potential and males with partners of childbearing potential:
             agreement to remain abstinent (refrain from heterosexual intercourse) or use
             contraceptive methods that result in a failure rate of < 1% per year during the
             treatment period and for at least 6 months after the last dose of sacituzumab
             govitecan for female patients and for at least 3 months for male patients; for at
             least 6 months after the last dose of capecitabine or carboplatin/cisplatin for female
             patients and for at least 3 months after the last dose of capecitabine or 6 months
             after the last dose of carboplatin/cisplatin for male patients. Examples of
             non-hormonal contraceptive methods with a failure rate of < 1% per year include:
             bilateral tubal ligation; male partner sterilization; intrauterine devices.

         23. Complete staging work-up prior to the initiation of neoadjuvant chemotherapy.

        Exclusion Criteria:

          1. Known hypersensitivity reaction to one of the compounds or substances used in this
             protocol.

          2. Patients with definitive clinical or radiologic evidence of stage IV cancer
             (metastatic disease) are not eligible.

          3. Patients with a history of any malignancy are ineligible with the following
             exceptions:

               -  Patient has been disease-free for at least 5 years and is at low risk for
                  recurrence of that malignancy

               -  CIS of the cervix, basal cell and squamous cell carcinomas of the skin.

          4. Female patients: pregnancy or lactation at the time of randomization or intention to
             become pregnant during the study and up to 6 months after sacituzumab govitecan and up
             to 6 months after treatment with capecitabine or carboplatin/cisplatin.

          5. Severe and relevant co-morbidity that would interact with the application of cytotoxic
             agents or the participation in the study, including Gilbert´s disease,
             Crigler-Najjar-Syndrome, known hepatitis B, hepatitis C, known HIV positivity or known
             autoimmune disease (other than diabetes, vitiligo, or stable thyroid disease) and
             infection requiring intravenous antibiotic use within 1 week of enrolment.

          6. Any condition that interferes with the safe administration of the treatment of
             physician´s choice in case the patient is randomized into the TPC arm.

          7. Known or suspected congestive heart failure (>NYHA I) and/or coronary heart disease,
             angina pectoris requiring antianginal medication, previous history of myocardial
             infarction, evidence of prior infarction on ECG, uncontrolled or poorly controlled
             arterial hypertension (i.e. BP >150/90 mmHg under treatment with at maximum three
             antihypertensive drugs), rhythm abnormalities requiring permanent treatment (excluding
             chronic atrial fibrillation not requiring a pacemaker), clinically significant
             valvular heart disease, supraventricular and nodal arrhythmias requiring a pacemaker
             or not controlled with medication;conduction abnormality requiring a pacemaker.

          8. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g. bronchiolitis
             obliterans), drug-induced pneumonitis, idiopathic pneumonitis or active pneumonitis on
             chest CT scan.

          9. Receipt of live attenuated vaccination within 30 days prior to study entry or within
             30 days of receiving chemotherapy.

         10. History of significant neurological or psychiatric disorders including psychotic
             disorders, dementia or seizures that would prohibit the understanding and giving of
             informed consent.

         11. Any condition that, in the opinion of the investigator, would interfere with
             evaluation of study treatment or interpretation of patient safety or study results.

         12. Known allergic reactions to irinotecan.

         13. Concurrent treatment with:

               -  Chronic corticosteroids prior to study entry with the exceptions of intranasal
                  and inhaled corticosteroids or systemic corticosteroids at physiological doses,
                  which are not to exceed 10 mg/day of prednisone, or equivalent corticosteroid.